Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Adjuvant endocrine therapy for breast cancer reduces recurrence and improves survival rates. Many patients never start treatment or discontinue prematurely. A better understanding of factors associated with endocrine therapy initiation and persistence could inform practitioners how to support patients. We analyzed data from a longitudinal study of 2,268 women diagnosed with breast cancer and reported to the Metropolitan Detroit and Los Angeles SEER cancer registries in 2005–2007. Patients were surveyed approximately both 9 months and 4 years after diagnosis. At the 4-year mark, patients were asked if they had initiated endocrine therapy, terminated therapy, or were currently taking therapy (defined as persistence). Multivariable logistic regression models examined factors associated with initiation and persistence. Of the 743 patients eligible for endocrine therapy, 80 (10.8 %) never initiated therapy, 112 (15.1 %) started therapy but discontinued prematurely, and 551 (74.2 %) continued use at the second time point. Compared with whites, Latinas (OR 2.80, 95 % CI 1.08–7.23) and black women (OR 3.63, 95 % CI 1.22–10.78) were more likely to initiate therapy. Other factors associated with initiation included worry about recurrence (OR 3.54, 95 % CI 1.31–9.56) and inadequate information about side effects (OR 0.24, 95 % CI 0.10–0.55). Factors associated with persistence included two or more medications taken weekly (OR 4.19, 95 % CI 2.28–7.68) and increased age (OR 0.98, 95 % CI 0.95–0.99). Enhanced patient education about potential side effects and the effectiveness of adjuvant endocrine therapy in improving outcomes may improve initiation and persistence rates and optimize breast cancer survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Health Belief Model: a decade later.
Janz, N. K., & Becker, M. H. (1984) · Health Education Quarterly · doi:10.1177/109019818401100101 · Cited by 8,437
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Horne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · cited 1×
“The high termination rate is consistent, however, with studies of medication use for other chronic conditions [28, 29].”
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674 · cited 1×
“Tamoxifen [1] and aromatase inhibitors [2] reduce mortality and longer duration of therapy provides greater benefit versus shorter duration [1, 3–5].”
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870 · cited 2×
“While rates of guideline-concordant prescribing of adjuvant hormonal therapy are high [17–19], a number of studies have documented that longterm persistence with prescribed endocrine therapy for breast cancer is alarmingly low [6–9, 20–26].”
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676 · cited 2×
“While rates of guideline-concordant prescribing of adjuvant hormonal therapy are high [17–19], a number of studies have documented that longterm persistence with prescribed endocrine therapy for breast cancer is alarmingly low [6–9, 20–26].”
The Role of Patient-Physician Trust in Moderating Medication Nonadherence Due to Cost Pressures
Piette, J. D., Heisler, M., Krein, S., & Kerr, E. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1749 · Cited by 388 · cited 1×
“Patient attributes such as older age, greater uncertainty about the marginal benefit of treatment, clinical indication for treatment, and more comorbid conditions have been associated with lower persistence, as have side-effects from therapy [21-22, 30] and higher out-of-pocket costs [31-33].”
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251 · cited 1×
“Between 33 and 40 % of patients terminate therapy before the recommended 5-year period, a discontinuation rate that is substantively higher than that reported in clinical trials [27].”
Cited by
Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Rowden, D., Solky, A. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2258 · Cited by 786
Self-citationWarner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1349 · Cited by 280
Lin, C., Clark, R., Tu, P., Bosworth, H. B., & Zullig, L. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4317-2 · Cited by 160
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Metadata
- Authors
- Friese, C. R., Pini, T. M., Li, Y., Abrahamse, P. H., Graff, J. J., Hamilton, A. S., Jagsi, R., Janz, N. K., Hawley, S. T., Katz, S. J., & Griggs, J. J.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2013-03-31
- Volume
- 138
- Issue
- 3
- Pages
- 931-939
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2143295270
- Cited by
- 85
- References
- 13
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. https://app.cochat.ai/papers/10.1007/s10549-013-2499-9
- The paper
- Friese, C. R., Pini, T. M., Li, Y., Abrahamse, P. H., Graff, J. J., Hamilton, A. S., Jagsi, R., Janz, N. K., Hawley, S. T., Katz, S. J., & Griggs, J. J. (2013). Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-013-2499-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.